/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Lipocine Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.094 -0.0492(-4.92%) LPCN at 04 Dec 2025 04:37 PM Biotechnology
Lowest Today 3.09
Highest Today 3.25
Today’s Open 3.25
Prev. Close 3.25
52 Week High 5.50
52 Week Low 2.52
Day’s Range: Low 3.09 High 3.25
52-Week Range: Low 2.52 High 5.50
1 day return -
1 Week return -
1 month return +21.34
3 month return +6.22
6 month return -3.45
1 year return -37.97
3 year return -58.2
5 year return -88.34
10 year return -

Institutional Holdings

Vanguard Group Inc 4.15

Vanguard Total Stock Mkt Idx Inv 2.63

BlackRock Inc 1.65

Geode Capital Management, LLC 1.13

Vanguard Institutional Extnd Mkt Idx Tr 0.94

Susquehanna International Group, LLP 0.85

Renaissance Technologies Corp 0.64

Fidelity Extended Market Index 0.54

Dimensional Fund Advisors, Inc. 0.44

State Street Corp 0.34

Northern Trust Corp 0.24

Extended Equity Market Fund K 0.23

Barclays PLC 0.17

Fidelity Total Market Index 0.16

Dimensional US Targeted Value ETF 0.15

Spartan Extended Market Index Pool F 0.15

Fidelity Series Total Market Index 0.14

Northern Trust Extended Eq Market Idx 0.14

NT Ext Equity Mkt Idx Fd - L 0.14

Blackrock US Eq Mkt Fund CF 0.13

DFA US Targeted Value I 0.13

U.S. Equity Market Fund F 0.11

NT Ext Equity Mkt Idx Fd - NL 0.09

T. Rowe Price U.S. Equities Tr 0.09

Fidelity Nasdaq Composite Index 0.08

Vanguard Instl Ttl Stck Mkt Idx Tr 0.08

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.07

Schwab Total Stock Market Index 0.05

Spartan Total Market Index Pool G 0.05

Bank of America Corp 0.05

Advisor Group Holdings, Inc. 0.04

Tower Research Capital LLC 0.01

Morgan Stanley - Brokerage Accounts 0.01

UBS Group AG 0.01

CALDWELL SUTTER CAPITAL INC 0.01

Group One Trading, LP 0.00

SBI Securities Co Ltd 0.00

Tidemark LLC 0.00

FMR Inc 0.00

JPMorgan Chase & Co 0.00

Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 18.04 M

PB Ratio 1.3505

PE Ratio 0.0

Enterprise Value 3.97 M

Total Assets 22.51 M

Volume 31252

Company Financials

Annual Revenue FY23:-3067006 -3.1M, FY22:500000 0.5M, FY21:16140838 16.1M, FY20:0 0.0M, FY19:164990 0.2M

Annual Profit FY23:null 0.0M, FY22:-8056888 -8.1M, FY21:8475279 8.5M, FY20:-9748469 -9.7M, FY19:-7303220 -7.3M

Annual Net worth FY23:-16299742 -16.3M, FY22:-10758636 -10.8M, FY21:-634399 -0.6M, FY20:-20964819 -21.0M, FY19:-13007344 -13.0M

Quarterly Revenue Q3/2025:114574 0.1M, Q2/2025:622849 0.6M, Q1/2025:93864 0.1M, Q3/2024:0 0.0M, Q2/2024:89565 0.1M

Quarterly Profit Q3/2025:114574 0.1M, Q2/2025:-1513920 -1.5M, Q1/2025:93864 0.1M, Q3/2024:null 0.0M, Q2/2024:-1785156 -1.8M

Quarterly Net worth Q3/2025:-3186832 -3.2M, Q2/2025:-2205716 -2.2M, Q1/2025:-1864873 -1.9M, Q3/2024:-2218818 -2.2M, Q2/2024:-3068634 -3.1M

Fund house & investment objective

Company Information Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Organisation Biotechnology

Employees 16

Industry Biotechnology

CEO Dr. Mahesh V. Patel Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow